Sotac Pharmaceuticals Limited (NSE:SOTAC)
India · Delayed Price · Currency is INR 128.50
0.00 (0.00%)
At close: Oct 23, 2025
Sotac Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
Operating Revenue | 969.87 | 1,038 | 774.83 | 731.52 | 488.43 | Upgrade |
Other Revenue | 32.7 | 1.35 | - | - | - | Upgrade |
| 1,003 | 1,040 | 774.83 | 731.52 | 488.43 | Upgrade | |
Revenue Growth (YoY) | -3.57% | 34.18% | 5.92% | 49.77% | 70.76% | Upgrade |
Cost of Revenue | 683.11 | 796.12 | 572.69 | 559.77 | 393.92 | Upgrade |
Gross Profit | 319.45 | 243.53 | 202.14 | 171.75 | 94.51 | Upgrade |
Selling, General & Admin | 35.25 | 40.36 | 42.93 | 30.04 | 31.78 | Upgrade |
Other Operating Expenses | 114.6 | 114.96 | 83.31 | 61.93 | 48.19 | Upgrade |
Operating Expenses | 188.21 | 186.33 | 149.01 | 103.24 | 105.9 | Upgrade |
Operating Income | 131.25 | 57.2 | 53.13 | 68.51 | -11.39 | Upgrade |
Interest Expense | -22.33 | -15.51 | -19.02 | -5.02 | -9.96 | Upgrade |
Interest & Investment Income | 5.57 | 1.82 | 0.46 | 0.48 | 0.74 | Upgrade |
Currency Exchange Gain (Loss) | - | -0.07 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -3.48 | -1.81 | -1.11 | 1.33 | 0.04 | Upgrade |
EBT Excluding Unusual Items | 111.01 | 41.63 | 33.47 | 65.31 | -20.57 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -18.36 | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.19 | - | - | - | - | Upgrade |
Other Unusual Items | -0 | -2.34 | 5.8 | - | - | Upgrade |
Pretax Income | 111.2 | 39.64 | 39.27 | 46.95 | -20.57 | Upgrade |
Income Tax Expense | 18.44 | 3.85 | 16.41 | 18.16 | 3.09 | Upgrade |
Earnings From Continuing Operations | 92.75 | 35.79 | 22.86 | 28.79 | -23.65 | Upgrade |
Minority Interest in Earnings | -12.49 | 7.02 | 5.93 | - | - | Upgrade |
Net Income | 80.27 | 42.81 | 28.79 | 28.79 | -23.65 | Upgrade |
Net Income to Common | 80.27 | 42.81 | 28.79 | 28.79 | -23.65 | Upgrade |
Net Income Growth | 87.48% | 48.69% | 0.02% | - | - | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 8 | 8 | 8 | Upgrade |
Shares Outstanding (Diluted) | 11 | 11 | 8 | 8 | 8 | Upgrade |
Shares Change (YoY) | 0.67% | 36.35% | - | - | 132.16% | Upgrade |
EPS (Basic) | 7.26 | 3.90 | 3.58 | 3.58 | -2.94 | Upgrade |
EPS (Diluted) | 7.26 | 3.90 | 3.58 | 3.58 | -2.94 | Upgrade |
EPS Growth | 86.15% | 9.04% | 0.02% | - | - | Upgrade |
Free Cash Flow | -213.47 | -338.65 | -8.57 | 28.46 | -34.68 | Upgrade |
Free Cash Flow Per Share | -19.32 | -30.85 | -1.06 | 3.54 | -4.31 | Upgrade |
Dividend Per Share | 0.100 | - | - | 2.000 | - | Upgrade |
Gross Margin | 31.86% | 23.42% | 26.09% | 23.48% | 19.35% | Upgrade |
Operating Margin | 13.09% | 5.50% | 6.86% | 9.37% | -2.33% | Upgrade |
Profit Margin | 8.01% | 4.12% | 3.72% | 3.94% | -4.84% | Upgrade |
Free Cash Flow Margin | -21.29% | -32.57% | -1.11% | 3.89% | -7.10% | Upgrade |
EBITDA | 169.54 | 88.16 | 75.89 | 79.77 | 14.54 | Upgrade |
EBITDA Margin | 16.91% | 8.48% | 9.79% | 10.90% | 2.98% | Upgrade |
D&A For EBITDA | 38.3 | 30.95 | 22.76 | 11.26 | 25.93 | Upgrade |
EBIT | 131.25 | 57.2 | 53.13 | 68.51 | -11.39 | Upgrade |
EBIT Margin | 13.09% | 5.50% | 6.86% | 9.37% | -2.33% | Upgrade |
Effective Tax Rate | 16.59% | 9.70% | 41.78% | 38.68% | - | Upgrade |
Revenue as Reported | 1,009 | 1,043 | 778.33 | 733.7 | 489.5 | Upgrade |
Advertising Expenses | 3.15 | 0.05 | 0.3 | 0.02 | - | Upgrade |
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.